All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Clinical Efficacy Evaluation and Long-Term Prognosis of Glucagon-Like Peptide-1 Combined with Sodium Glucose Cotransporter-2 Inhibitor in Diabetes

Author(s): Yan Pi, Ting Ting Du and Ping Zhao*
Department of Endocrinology, Chongqing Seventh People’s Hospital, Banan, Chongqing 400054, 1Dianjiang People’s Hospital of Chongqing, Chongqing 4008300, China

Correspondence Address:
Ping Zhao, Dianjiang People’s Hospital of Chongqing, Chongqing 4008300, China, E-mail:

To investigate the clinical worth of glucagon-like peptide-1 receptor agonist (liraglutide) combined with sodium glucose cotransporter-2 inhibitor (dapagliflozin) in the treatment of overweight or obesity patients with type 2 diabetes mellitus and to explore whether the beneficial effect of the combination can persist during a 1 y follow-up. Eighty overweight or obesity type 2 diabetes mellitus patients admitted to a hospital from January 2019 to January 2020 were randomly divided into a control group and an observation group, with 40 cases in each group. The control group was treated with liraglutide and the experimental group was treated with basic dapagliflozin in the control group. All patients were continuously treated for 12 w. The measurement results of parameters before and after treatment, the changes in glucose metabolism parameters, blood lipid metabolism parameters and the occurrence of adverse reactions during treatment were recorded. After that, 74 treated patients were followed up for 1 y (6 refused) and measurements of various parameters were recorded. The differences in body mass index, waist circumference, hemoglobin A1c, fasting plasma glucose, triglyceride, total cholesterol, high-density lipoprotein cholesterol, lowdensity lipoprotein cholesterol, homeostatic model assessment-insulin resistance, homeostatic model assessment-beta and insulin sensitivity index before and after treatment in the experimental group were higher than those in the control group (p<0.05). Weight loss during treatment was sustained over 1 y in both groups, with more significant changes in the experimental group. The combination of glucagon-like peptide-1 agonist and sodium glucose cotransporter-2 inhibitor can improve diabetes in overweight or obesity patients with type 2 diabetes mellitus and effectively reduce blood glucose and body mass index, which is of great significance for reducing body weight and improving efficacy. Therefore, using glucagonlike peptide-1 agonists and sodium glucose cotransporter-2 inhibitors in overweight, diabetic patients is a promising option.

Full-Text | PDF

Google scholar citation report
Citations : 69022

Indian Journal of Pharmaceutical Sciences received 69022 citations as per google scholar report